

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/008035-2024>

Planning

NHS Framework Agreement for the supply of licenced Human Albumin Solution & Normal and Anti-D Immunoglobulins

NHS England

F01: Prior information notice

Prior information only

Notice identifier: 2024/S 000-008035

Procurement identifier (OCID): ocds-h6vhtk-044823

Published 13 March 2024, 1:47pm

Section I: Contracting authority

I.1) Name and addresses

NHS England

1st Floor, Quarry House, Quarry Hill

Leeds

LS2 7UE

Contact

Jennifer Tierney

Email

Jennifer.Tierney@england.nhs.uk

Country

United Kingdom

Region code

UKE - Yorkshire and the Humber

Internet address(es)

Main address

<https://www.england.nhs.uk/>

Buyer's address

<https://www.england.nhs.uk/>

I.3) Communication

Additional information can be obtained from the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

<https://health-family.force.com/s/Welcome>

I.4) Type of the contracting authority

Ministry or any other national or federal authority

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

NHS Framework Agreement for the supply of licenced Human Albumin Solution & Normal and Anti-D Immunoglobulins

Reference number

CM/PHS/23/5703

II.1.2) Main CPV code

- 33651520 - Immunoglobulins

II.1.3) Type of contract

Supplies

II.1.4) Short description

This market engagement relates to the NHS Framework Agreement for the supply of licenced Human Albumin Solution & Normal and Anti-D Immunoglobulins. The framework is anticipated to commence on 1 January 2025 for a period of 36 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. Total maximum framework agreement including extension options will be no more than 48 months. The purpose of the PIN is to engage with the supply market on the procurement approach and to understand market and supplier capacities prior to the Invitation to Tender.

II.1.5) Estimated total value

Value excluding VAT: £1,400,000,000

II.1.6) Information about lots

This contract is divided into lots: Yes

II.2) Description

II.2.1) Title

1-7

Lot No

1-7

II.2.2) Additional CPV code(s)

- 33651520 - Immunoglobulins

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Framework intended for use by the NHS in England, Northern Ireland, Scotland. The agreement may also be used by private sector contractors and agents working on behalf of the above.

II.2.4) Description of the procurement

This market engagement relates to the NHS Framework Agreement for the supply of licenced Human Albumin Solution & Normal and Anti-D Immunoglobulins. The framework is anticipated to commence on 1 January 2025 for a period of 36 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. Total maximum framework agreement including extension options will be no more than 48 months. The purpose of the PIN is to engage with the supply market on the procurement approach and to understand market and supplier capacities prior to the Invitation to Tender.

II.3) Estimated date of publication of contract notice

28 May 2024

Section IV. Procedure

IV.1) Description

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section VI. Complementary information

VI.3) Additional information

This market engagement relates to the NHS Framework Agreement for the supply of licenced Human Albumin Solution & Normal and Anti-D Immunoglobulins. The framework is anticipated to commence on 1 January 2025 for a period of 36 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. Total maximum framework agreement including extension options will be no more than 48 months.

The purpose of the PIN is to engage with the supply market on the procurement approach and to understand market and supplier capacities prior to the Invitation to Tender.

The market engagement documents will be made available during March for unrestricted and full direct access, free of charge, at <http://health.atamis.co.uk> under project reference C228466.

Please be aware the NHSE principal address has changed to Wellington House 133-155 Waterloo Road London SE1 8UG